SCHEMBL3211241

SCHEMBL3211241

[CH2]CCc1ccc(OCCOC)cc1OC1CCCCC1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PARP15 Q460N3 1/20 0.36
PARP10 Q53GL7 1/20 0.36
HRH3 Q9Y5N1 1/20 0.35
PPARG P37231 4/20 0.35
ERBB2 P04626 1/20 0.35
EPHX2 P34913 2/20 0.35
MET P08581 1/20 0.35
PDE4A P27815 2/20 0.34
PDE4B Q07343 2/20 0.34
PDE4C Q08493 2/20 0.34
PDE4D Q08499 2/20 0.34
KDM4E B2RXH2 1/20 0.34
MEN1 O00255 2/20 0.34
KMT2A Q03164 2/20 0.34
NPY1R P25929 1/20 0.34
NPY2R P49146 1/20 0.34
PPARD Q03181 1/20 0.34
PPARA Q07869 1/20 0.34
CNR1 P21554 1/20 0.33
CNR2 P34972 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3213102 0.86 CNR1 (0.38) PARP15PARP10HRH3PPARGERBB2
SCHEMBL3217512 0.80 BRD4 (0.41) PARP15PARP10ERBB2PDE4BMEN1
SCHEMBL3217506 0.80 CNR1 (0.39) PARP15PARP10PDE4APDE4BPDE4C
SCHEMBL3216035 0.76 RAB9A (0.40) FFAR1
SCHEMBL4666259 0.76 PPARG (0.42) PARP15PARP10PPARGEPHX2PDE4A
SCHEMBL4632439 0.74 PDE4D (0.42) ERBB2EPHX2METPDE4APDE4B
SCHEMBL27716295 0.73 PPARG (0.44) PPARGERBB2EPHX2METPDE4A
SCHEMBL3217588 0.73 PPARG (0.59) PPARGCNR1CNR2
SCHEMBL3206472 0.72 ABCB1 (0.47) KDM4EMEN1KMT2AFFAR1
SCHEMBL4600790 0.72 PPARG (0.40) PPARGPDE4APDE4BPDE4CPDE4D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100041892-A1 Therapeutic agent for diabetes ABE HIDENORI 2010-02-18 US disclosed
US-20090270631-A1 Therapeutic agent for diabetes ABE HIDENORI 2009-10-29 US disclosed
EP-1912645-A2 THERAPEUTIC AGENT FOR DIABETES Takeda Pharmaceutical Company Limited (JP) 2008-04-23 EP disclosed
US-20080009530-A1 Therapeutic Agent for Diabetes TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-01-10 US disclosed
WO-2007018314-A2 THERAPEUTIC AGENT FOR DIABETES TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-02-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090270631-A1 Therapeutic agent for diabetes FABP4, SLC5A1, SLC5A2 PARP15 3999/4885PARP10 4062/4885HRH3 4643/4885
US-20080009530-A1 Therapeutic Agent for Diabetes FABP4, SLC5A1, SLC5A2 PARP15 4134/4885PARP10 3910/4885HRH3 4767/4885
US-20100041892-A1 Therapeutic agent for diabetes FABP4, SLC5A1, SLC5A2 PARP15 3999/4885PARP10 4062/4885HRH3 4643/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.